Literature DB >> 19251247

Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects.

Robert M Kessler1, Neil D Woodward, Patrizia Riccardi, Rui Li, M Sib Ansari, Sharlett Anderson, Benoit Dawant, David Zald, Herbert Y Meltzer.   

Abstract

BACKGROUND: Studies in schizophrenic patients have reported dopaminergic abnormalities in striatum, substantia nigra, thalamus, anterior cingulate, hippocampus, and cortex that have been related to positive symptoms and cognitive impairments.
METHODS: [(18)F]fallypride positron emission tomography studies were performed in off-medication or never-medicated schizophrenic subjects (n = 11, 6 men, 5 women; mean age of 30.5 +/- 8.0 [SD] years; 4 drug-naive) and age-matched healthy subjects (n = 11, 5 men, 6 women, mean age of 31.6 +/- 9.2 [SD]) to examine dopamine D(2) receptor (DA D(2)r) levels in the caudate, putamen, ventral striatum, medial thalamus, posterior thalamus, substantia nigra, amygdala, temporal cortex, anterior cingulate, and hippocampus.
RESULTS: In schizophrenic subjects, increased DA D(2)r levels were seen in the substantia nigra bilaterally; decreased levels were seen in the left medial thalamus. Correlations of symptoms with ROI data demonstrated a significant correlation of disorganized thinking/nonparanoid delusions with the right temporal cortex ROI (r = .94, p = .0001), which remained significant after correction for multiple comparisons (p < .03). Correlations of symptoms with parametric images of DA D(2)r levels revealed no significant clusters of correlations with negative symptoms but significant clusters of positive correlations of total positive symptoms, delusions and bizarre behavior with the lateral and anterior temporal cortex, and hallucinations with the left ventral striatum.
CONCLUSIONS: The results of this study demonstrate abnormal DA D(2)r-mediated neurotransmission in the substantia nigra consistent with nigral dysfunction in schizophrenia and suggest that both temporal cortical and ventral striatal DA D(2)r mediate positive symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251247      PMCID: PMC2951678          DOI: 10.1016/j.biopsych.2008.12.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  83 in total

1.  Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area.

Authors:  S R Sesack; V M Pickel
Journal:  J Comp Neurol       Date:  1992-06-08       Impact factor: 3.215

2.  Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold.

Authors:  S D Forman; J D Cohen; M Fitzgerald; W F Eddy; M A Mintun; D C Noll
Journal:  Magn Reson Med       Date:  1995-05       Impact factor: 4.668

Review 3.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

4.  Elevated dopa decarboxylase activity in living brain of patients with psychosis.

Authors:  J Reith; C Benkelfat; A Sherwin; Y Yasuhara; H Kuwabara; F Andermann; S Bachneff; P Cumming; M Diksic; S E Dyve; P Etienne; A C Evans; S Lal; M Shevell; G Savard; D F Wong; G Chouinard; A Gjedde
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

5.  The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia.

Authors:  D G Daniel; D R Weinberger; D W Jones; J R Zigun; R Coppola; S Handel; L B Bigelow; T E Goldberg; K F Berman; J E Kleinman
Journal:  J Neurosci       Date:  1991-07       Impact factor: 6.167

6.  Patterns of cerebral blood flow in schizophrenia.

Authors:  P F Liddle; K J Friston; C D Frith; S R Hirsch; T Jones; R S Frackowiak
Journal:  Br J Psychiatry       Date:  1992-02       Impact factor: 9.319

Review 7.  The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.

Authors:  A Y Deutch
Journal:  J Neural Transm Suppl       Date:  1992

8.  In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.

Authors:  G D Pearlson; D F Wong; L E Tune; C A Ross; G A Chase; J M Links; R F Dannals; A A Wilson; H T Ravert; H N Wagner
Journal:  Arch Gen Psychiatry       Date:  1995-06

9.  Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

Authors:  J Hietala; E Syvälahti; K Vuorio; K Någren; P Lehikoinen; U Ruotsalainen; V Räkköläinen; V Lehtinen; U Wegelius
Journal:  Arch Gen Psychiatry       Date:  1994-02

10.  Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets.

Authors:  S R Sesack; C Aoki; V M Pickel
Journal:  J Neurosci       Date:  1994-01       Impact factor: 6.167

View more
  55 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

3.  Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia.

Authors:  Stefano Marenco; Jason L Stein; Antonina A Savostyanova; Fabio Sambataro; Hao-Yang Tan; Aaron L Goldman; Beth A Verchinski; Alan S Barnett; Dwight Dickinson; José A Apud; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 4.  Concise review: the promise of human induced pluripotent stem cell-based studies of schizophrenia.

Authors:  Kristen J Brennand; Fred H Gage
Journal:  Stem Cells       Date:  2011-12       Impact factor: 6.277

5.  The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations.

Authors:  Ingo Vernaleken; Lisa Peters; Mardjan Raptis; Robert Lin; Hans-Georg Buchholz; Yun Zhou; Oliver Winz; Frank Rösch; Peter Bartenstein; Dean F Wong; Wolfgang M Schäfer; Gerhard Gründer
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-18       Impact factor: 6.200

6.  Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors:  Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

Review 7.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 8.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

9.  Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals.

Authors:  Orjan de Manzano; Simon Cervenka; Anke Karabanov; Lars Farde; Fredrik Ullén
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

10.  Timing of moderate level prenatal alcohol exposure influences gene expression of sensory processing behavior in rhesus monkeys.

Authors:  Mary L Schneider; Colleen F Moore; Julie A Larson; Christina S Barr; Onofre T Dejesus; Andrew D Roberts
Journal:  Front Integr Neurosci       Date:  2009-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.